Lilly Launches guide to Empower Patients with Alopecia Areata and Reduce Stigma
Madrid,Spain – Pharmaceutical company Lilly has released a new guide aimed at improving communication between patients and healthcare professionals regarding alopecia areata,an autoimmune condition causing hair loss. The initiative seeks to address the notable emotional and psychological burden experienced by individuals with the condition and to dismantle the stigma surrounding it.
Alopecia areata affects an estimated 1-2% of the population globally, manifesting in various forms, including patchy hair loss (alopecia areata), total hair loss on the scalp (alopecia totalis), and complete body hair loss (alopecia universalis) [1]. The condition can develop at any age and is not limited by gender, though it can present differently in men and women. Recent research highlights the considerable impact on quality of life, with patients reporting feelings of anxiety, depression, and social isolation [7].
“People with alopecia areata, particularly women, often feel invisible and face a lack of understanding. Initiatives like ‘No es solo pelo’ [It’s not just hair] and projects like this guide are crucial for raising awareness and destigmatizing our condition,” stated a representative from a patient advocacy group.
The newly released guide from Lilly is designed to encourage patients to openly discuss their concerns with their doctors, fostering a trusting relationship that can lead to better health outcomes. “Lilly is committed to eliminating the stigma associated with alopecia areata,” explained José Antonio Sacristán,Medical Director of Lilly Spain. “This guide aims to empower patients to ask the questions that matter to them, promoting a patient-physician dialog built on trust, wich will likely translate into improved healthcare results.”
Understanding Alopecia Areata:
Alopecia areata is characterized by the immune system mistakenly attacking hair follicles,leading to hair loss. Diagnosis often involves a clinical examination, and a dermoscopy (trichoscopy) can be a valuable tool for identifying specific patterns associated with the condition [2, 5]. The severity of alopecia areata varies greatly, ranging from small, localized patches to extensive hair loss.
Resources for Patients and Healthcare Professionals:
* Asociación Alopecia Comunidad de Madrid (ACMA): https://asociacionalopeciamadrid.com/conoce-la-alopecia#INDEX1
* Libro Blanco de la Alopecia Areata en España (White Paper on Alopecia Areata in Spain): https://aedv.es/wp-content/uploads/2023/06/libro-Blanco-Alopecia-Areata_VE2.0.pdf [3]
References:
- Lee HH, Gwillim E, Patel KR et al. epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. J Am Acad Dermatol 2020;82(3):675-82.
- Gómez-Quispe H, Muñoz Moreno-Arrones O, Hermosa-gelbard Á, Vañó-Galván S, Saceda-Corralo D. Tricoscopia en la alopecia areata. ActasDermosifiliogr. Published online January 2022.doi:10.1016/j.ad.2022.08.018.
- Asociación Alopecia Comunidad de Madrid; Consejo General de Colegios Farmacéuticos. (2023). Libro Blanco de la Alopecia Areata en España.
- Juárez-Rendón KJ, Sánchez GR, Reyes-López M, García-Ortiz JE